Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TPST-1495 |
Synonyms | |
Therapy Description |
TPST-1495 is a dual antagonist that selectively inhibits EP2 and EP4, and reverses Prostaglandin E2 mediated immune suppression, potentially resulting in enhanced antitumor immune response and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2019;7:282, Abs nr: P311). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TPST-1495 | TPST1495|TPST 1495 | TPST-1495 is a dual antagonist that selectively inhibits EP2 and EP4, and reverses Prostaglandin E2 mediated immune suppression, potentially resulting in enhanced antitumor immune response and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2019;7:282, Abs nr: P311). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
NCT06129604 | Phase II | TPST-1495 | Pilot Window of Opportunity Trial (POET) | Recruiting | USA | 0 |